Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

NCT01780545 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Urothelial Carcinoma

Interventions

DRUG: OGX-427
DRUG: Docetaxel

Sponsor

Noah Hahn, M.D.

Collaborators

[object Object]
[object Object]